Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska reiterates an Overweight rating on Celldex Therapeutics (NASDAQ:CLDX) and maintains a $67 price target.
July 30, 2024 | 1:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska reiterates an Overweight rating on Celldex Therapeutics (NASDAQ:CLDX) and maintains a $67 price target.
The reiteration of an Overweight rating and a maintained price target of $67 by a reputable analyst from Cantor Fitzgerald is likely to positively impact the stock price of Celldex Therapeutics in the short term. This indicates continued confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100